Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of the study is to assess the immunogenicity of DAC HYP 150 mg administered every 4 weeks by an SC injection using the pre-filled syringe (PFS) in subjects with RRMS.
Critère d'inclusion
- Relapsing-Remitting Multiple Sclerosis